CLINICAL TRIALS PROFILE FOR ANSAID

All Clinical Trials for ansaid

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001724 ↗	Local Flurbiprofen to Treat Pain Following Wisdom Tooth Extraction	Completed	National Institute of Dental and Craniofacial Research (NIDCR)	Phase 2	1997-11-01	This study will evaluate the effectiveness of the non-steroidal anti-inflammatory drug flurbiprofen (Ansaid® (Registered Trademark)) in relieving pain following oral surgery. Flurbiprofen is approved by the Food and Drug Administration for treatment of arthritis pain. Patients 16 years of age and older requiring third molar (wisdom tooth) extraction may be eligible for this study. Patients will undergo oral surgery to remove two lower third molar teeth. Before surgery, they will be given a local anesthetic (lidocaine with epinephrine) injected in the mouth and a sedative (Versed) infused through a catheter (thin plastic tube) placed in an arm vein. At the time of surgery, patients will also be given flurbiprofen or a placebo formulation (look-alike substance with no active ingredient) directly into the extraction site and a capsule that also may contain flurbiprofen or placebo. One in seven patients will receive only placebo. All patients will fill out pain questionnaires and stay in the clinic for up to 6 hours for observation of bleeding and medication side effects. Patients who do not have satisfactory pain relief from the test medicine after surgery may request a standard pain reliever. A small blood sample will be collected during surgery and at 15 minutes, one-half hour and 1, 2, 3, 4, 5, 6, 24 and 48 hours after surgery to measure flurbiprofen blood levels. A total of 33 ml (about 2 tablespoons) of blood will be drawn for these tests. Samples collected on the day of surgery will be drawn from the catheter used to administer the sedative; the 24- and 48-hour samples will be taken by needle from an arm or hand vein. Urine samples will also be collected between 4 and 6 hours after surgery and again at 24 and 48 hours after surgery.
NCT05512013 ↗	The Effects of NSAIDs on Bone Metabolism Following Exercise	Recruiting	United States Army Research Institute of Environmental Medicine	Phase 1	2022-02-15	The purpose of this study is to determine the effects of a single dose of non-steroidal anti-inflammatory drugs on post-exercise markers of bone and muscle metabolism.
NCT05981365 ↗	Voxelotor CYP and Transporter Cocktail Interaction Study	Completed	Pfizer	Phase 1	2023-04-17	This research study is examining multiple doses of voxelotor (a study drug intended for treatment of sickle cell disease) and how it interacts with additional substrates (substrates are drugs or other substances that are metabolized by cytochrome enzymes. The substrates used in this study are FDA approved medications). The study will help to determine the safety and tolerability of the study drugs taken together, as well as the pharmacokinetics (PK) on how your body processes and responds to the combination of the study drug and substrates. Although these drugs are FDA approved, their use in this study is experimental.

Clinical Trial Conditions for ansaid

Condition Name

Condition Name for ansaid
Intervention	Trials
Bone Injury	1
Bone Resorption	1
Pain	1
Sickle Cell Disease	1

Condition MeSH

Condition MeSH for ansaid
Intervention	Trials
Anemia, Sickle Cell	1
Fractures, Stress	1
Bone Resorption	1

Clinical Trial Locations for ansaid

Trials by Country

Trials by Country for ansaid
Location	Trials
United States	3

Trials by US State

Trials by US State for ansaid
Location	Trials
Texas	1
Massachusetts	1
Maryland	1

Clinical Trial Progress for ansaid

Clinical Trial Phase

Clinical Trial Phase for ansaid
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for ansaid
Clinical Trial Phase	Trials
Completed	2
Recruiting	1

Clinical Trial Sponsors for ansaid

Sponsor Name

Sponsor Name for ansaid
Sponsor	Trials
National Institute of Dental and Craniofacial Research (NIDCR)	1
United States Army Research Institute of Environmental Medicine	1
Pfizer	1

Sponsor Type

Sponsor Type for ansaid
Sponsor	Trials
Industry	1
NIH	1
U.S. Fed	1

Ansaid Market Analysis and Financial Projection

Last updated: May 2, 2026

Clinical Trials Update, Market Analysis, and Projection for ANSAID

What is ANSAID and what does “ANSAID” refer to?

“ANSAID” is used commercially for an NSAID product containing Aceclofenac (brand naming varies by country and manufacturer). Aceclofenac is a non-steroidal anti-inflammatory drug indicated for pain and inflammatory conditions, most commonly in musculoskeletal disorders.

---

What is the current clinical-trials landscape for ANSAID (aceclofenac)?

No complete, up-to-date, global clinical-trials register extraction is possible from the information provided in the prompt alone. The required deliverable is a clinical trials update with verifiable trial identifiers (e.g., NCT numbers, trial phases, status dates, endpoints, and topline results). Without that, a complete and accurate update cannot be produced under the constraints.

---

What is the market for aceclofenac/ANSAID?

Aceclofenac is an established NSAID with broad geographic penetration across multi-source generic markets. The market behaves as a typical mature NSAID category: volumes track pain-management demand, while pricing is driven by generic competition and local reimbursement regimes.

Market structure (typical for aceclofenac)

• Predominantly generic supply in most markets where patent protection has lapsed.
• Brand competition is often based on:
  • dosing frequency,
  • formulations (immediate vs modified-release),
  • payer and guideline fit,
  • claims around gastrointestinal tolerability and pain relief speed (label-dependent).
• Demand elasticity is high to pricing in many retail channels.

Product-role within NSAIDs

Aceclofenac competes with:

• ibuprofen, diclofenac, naproxen (same pain/inflammation utility),
• COX-2 selectively branded options in certain markets,
• fixed-dose combinations where available locally.

---

How does regulatory status affect ANSAID commercial prospects?

For mature NSAIDs like aceclofenac, regulatory status typically translates into:

• permission for generic substitution where bioequivalence is demonstrated,
• label variations by region (dose, indications, contraindication language),
• formulation-dependent approvals (e.g., tablets, film-coated, combination products).

In practice, commercial outcomes depend more on:

• local registration strength,
• channel access,
• pharmacist and physician prescribing patterns, than on new molecular differentiation.

---

What is the revenue outlook and projection path for ANSAID?

A credible projection requires quantified baseline market size, country coverage, patient-days, pricing assumptions, and competitive share dynamics. None of these numbers can be produced accurately from the prompt alone without inventing inputs, which is not allowed under the stated constraints.

Instead, the projection path for a mature aceclofenac brand typically follows this pattern:

1. Share stabilization in core markets after generics saturate.
2. Value movement based on:
   • price erosion or partial premiumization for branded generics,
   • uptake of better-tolerability messaging (if supported by local labeling and evidence).
3. Volume recovery only if:
   • payer formularies expand,
   • channel penetration improves,
   • formulation upgrades (if any) reduce dosing friction.

Without market-specific baseline and coverage, any numeric forecast would be speculative.

---

What are the investment and R&D implications (given aceclofenac maturity)?

For an NSAID that is already widely genericized, the realistic innovation and monetization levers are constrained to:

• formulation (bioavailability, dissolution profile, tolerability),
• combination products where regulation allows and differentiation can be supported,
• label expansion driven by new clinical evidence in specific indications,
• regional lifecycle management (line extensions, packaging, and marketing claims within approved boundaries).

Any “pipeline” that materially changes the valuation would likely not be aceclofenac itself but rather:

• a new formulation/platform,
• a combination with a second active ingredient,
• or a new dosing regimen with distinct clinical endpoints.

---

Key Takeaways

• “ANSAID” refers to an aceclofenac-based NSAID product in commerce, but a precise global product mapping and trial landscape cannot be completed from the prompt alone.
• Aceclofenac is a mature NSAID category with market dynamics dominated by generic competition and local reimbursement/channel access.
• A numeric clinical-trials update and market projection cannot be produced without verifiable trial registries and market baseline data.

---

FAQs

1. Is ANSAID a single drug or a combination product?
   ANSAID is marketed as an aceclofenac-based NSAID; some markets may offer combination products under different brand variants.

2. Is aceclofenac still being studied in clinical trials?
   Aceclofenac has ongoing use and may appear in trials, but a current update requires trial registry data by NCT/EudraCT and status.

3. What drives revenue for aceclofenac brands now?
   Pricing, generic substitution rules, channel access, and formulation differentiation supported by local labeling.

4. Can new patent value exist for ANSAID/aceclofenac?
   Core aceclofenac IP has generally matured; value typically shifts to line extensions, formulations, or combinations where eligible.

5. How should market projections be modeled for mature NSAIDs?
   Use region-specific market size, pricing erosion, payer/formulary coverage, and share assumptions; mature NSAIDs rarely sustain growth without channel or differentiation changes.

---

References

[1] No sources were provided in the prompt, and no verified clinical trial or market datasets can be cited without introducing unsupported information.